Back to news

Mesoblast Showcased at ASX Premier Investor Day Event

Globe Newswire•15/11/2026•18:16 ET
1

Key Highlights

  • ➤Mesoblast highlighted commercial-stage transformation at ASX Investor Day.
  • ➤Ryoncil growth and adult acute graft-versus-host disease expansion identified as priorities.
  • ➤Rexlemestrocel-L advanced for inflammatory chronic low back pain.
  • ➤Heart failure and pulmonary hypertension programs target cardiopulmonary indications.
  • ➤Mesoblast plans disciplined capital deployment for commercial growth and late-stage development.

NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities Exchange (ASX) Investor Day in Melbourne at the session titled “Meet the CEO: Inside Australia’s Listed Companies.”

The presentation highlighted Mesoblast’s transformation into a commercial-stage biotechnology company, continued growth of Ryoncil(®) (remestemcel-L-rknd) and the opportunity to leverage the Company’s cellular therapy platform across multiple high-value indications.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in